HBIO Q4 revenue $28.4M (-14% YoY), GAAP net loss $1.7M; guides low-single-digit growth in FY23

HARVARD BIOSCIENCE INC

Revenues $28.4M, down 14% YoY; negative currency impact of $1.0M.
GAAP operating loss $0.5M vs income $1.7M; GAAP diluted EPS -$0.04 vs $0.02.
Adjusted EPS $0.04 vs $0.08; adjusted EBITDA $3.7M vs $5.7M.
FY23 guidance: low-to-mid single-digit revenue growth, improving gross margin, adjusted EBITDA expansion.
Plans to reduce leverage ratio to ~2x by year end with improved margins and working capital.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

HARVARD BIOSCIENCE INC reported the fourth quarter and year ended December 31, 2022 results: revenue $28.4 million, net income $(1.7) M, EPS $(0.04).

Period: the fourth quarter and year ended December 31, 2022
Revenue: $28.4 million
Net income: $(1.7) M
EPS: $(0.04)
Result: reported results

Exact text from the filing

Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2022. Our fourth quarter revenues were $28.4 million, down 14% versus the comparable prior year period, including a negative currency impact of $1.0 million. During the quarter ended December 31, 2022, our cellular and molecular

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

HARVARD BIOSCIENCE INC filing history →

Source: SEC EDGAR

accession 0001171843-23-001518

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.